



EIKO LIFESCIENCES LIMITED

FEEL THE CHEMISTRY

Ref. No.: EIKO/BSE/2021-22/18

Dated: 16.09.2021

To,
Corporate Services Department,
BSE Limited,
P J Towers, 1st Floor, Dalal Street,
Fort, Mumbai - 400001.

BSE Scrip Code: EIKO 540204

Sub: Statement of Deviation or Variation in utilization of funds raised under Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the Quarter ended June 30, 2021

Ref: Eiko Lifesciences Limited
BSE Scrip Code: EIKO 540204

Dear Sir,

Please find enclosed herewith the Statement of Deviation or Variation in utilization of funds raised through Preferential Allotment by the Company in FY 2021-22 respectively under Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the quarter ended June 30, 2021.

Further note, that as per Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 every listed entity is required to file statement of deviation(s) or variation(s) till such time the issue proceeds have been fully utilised or the purpose for which these proceeds were raised has been achieved.

Therefore, our Company which has raised fund on May 12, 2021 (filed return of allotment) and utilised the fund before June 30, 2021, is not required to file the said statement as fund was fully utilised in the same quarter but as good Corporate Governance practice our Company has filed the same.

We request you to take note of the record

Thanking you.

Yours Sincerely,

For EIKO LIFESCIENCES LIMITED

L.K. Kabra

Laxmikant Kabra
(Director)
DIN: 00061346



Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity				Eiko Lifescience Limited		
Mode of Fund Raising				Preferential Issue		
Date of Raising Funds				12-05-2021		
Amount Raised				Rs 21,75,40,010/-		
Report filed for Quarter ended				30-06-2021		
Monitoring Agency				NA		
Monitoring Agency Name, if applicable				NA		
Is there a Deviation / Variation in use of funds raised				No		
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders				NA		
If Yes, Date of shareholder Approval				NA		
Explanation for the Deviation / Variation				NA		
Comments of the Audit Committee after review				No Comments		
Comments of the auditors, if any				No Comments		
Objects for which funds have been raised and where there has been a deviation, in the following table				-		
Original Object	Modified Object if any	Original Allocation	Modified allocation if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
To meet day to day operating expenses i.e working capital of the company as well as expansion of business activities which would be in the interest of the company to fulfill its growth strategies	NA	Rs 21,75,40,010/-	NA	Rs 21,75,40,010/-	NA	Nil

For EIKO LIFESCIENCES LIMITED

L.K. Kabra
Laxmikant Kabra
 (Director)
 DIN: 00061346

